FDA Approves Skyrizi for Pediatric Psoriasis and Psoriatic Arthritis Treatments

Children aged 6 and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis now have access to risankizumab (Skyrizi), a groundbreaking biologic approved by the FDA. This advancement addresses previously limited treatment options for young patients, offering targeted therapy for both skin and joint manifestations of psoriatic disease.

Risankizumab, a monoclonal antibody that inhibits the p19 subunit of IL-23, was first approved for adults in 2019 and has since been extended to pediatric populations. The approval is supported by data from the Phase 3 OptIMMize trial, which demonstrated high response rates in children and adolescents. Key findings include an 86.7% PASI75 reduction in children aged 6–11 and 85.2% in adolescents aged 12–17 at week 16, with durable outcomes through 52 weeks of treatment.

For children weighing under 40 kg, a new 55 mg prefilled syringe was introduced to ensure precise weight-based dosing, addressing gaps in pediatric care. The standard dosing regimen remains consistent with adult protocols, administered every 12 weeks after an initial and 4-week follow-up dose.

Clinical Significance

This approval represents a critical milestone for pediatric patients, as biologics like Skyrizi now offer safe, effective options for severe cases. Previously, children often received adult formulations off-label, which posed pharmacokinetic challenges. The study data and pharmacokinetic modeling confirm its safety and efficacy in this demographic, aligning with established adult safety profiles.

Mechanism and Efficacy

By blocking IL-23, risankizumab disrupts the inflammatory pathways responsible for skin plaques and joint inflammation. The drug’s high rates of PASI100 (complete skin clearance) in both children and adolescents highlight its potency. In children 6–11, 43.3% achieved PASI100, while 90% reached “clear or almost clear” skin assessments.

Clinical Considerations

Physicians should evaluate patients for eligibility based on disease severity and prior treatment responses. Standard pre-biologic screenings, including tuberculosis and hepatitis B testing, remain essential. The approval also aligns with European regulatory milestones, expanding global access for affected families.

Access and Support

Skyrizi is a specialty medication, with coverage dependent on individual insurance plans. AbbVie’s myAbbVie Assist program provides financial assistance for eligible patients. Families are encouraged to consult pediatric dermatologists or rheumatologists to discuss treatment options and eligibility.

Summary

Skyrizi’s FDA approval for children aged 6 and older marks a transformative step in managing severe psoriatic conditions. With robust clinical data and weight-based dosing, it offers a safer, more tailored alternative to previous therapies, improving quality of life for young patients affected by psoriasis and psoriatic arthritis.

Source link